-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Theriva Biologics
- The Trade: Theriva Biologics, Inc. (NYSE:TOVX) CEO and CFO Steven A Shallcross bought a total of 25,000 shares at an average price of $0.75. To acquire these shares, it cost around $18.7 thousand.
- What's Happening: Theriva Biologics received a notice of allowance for its U.S. patent application 16/982,211 titled "Alkaline Phosphatase Agents For Treatment Of Radiation Disorders."
- What Theriva Biologics Does: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs.
United States Antimony
- The Trade: United States Antimony Corporation (NYSE:UAMY) Director Lloyd Bardswich acquired a total of 10,000 shares at an average price of $0.44. The insider spent around $4.4 thousand to buy those shares.
- What's Happening: On Nov. 21, 2022, United States Antimony's board approved a 5 million share stock buy back.
- What United States Antimony Does: United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company.
Check This Out: 5 Most Expensive Consumer Stocks You Should Worry About
Context Therapeutics
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,839 shares at an average price of $0.72. To acquire these shares, it cost around $4.9 thousand.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
Don't forget to check out our premarket coverage here
Precipio
- The Trade: Precipio, Inc. (NASDAQ:PRPO) Director Sandberg Richard acquired a total of 20,000 shares at an average price of $0.78. The insider spent $15.53 thousand to buy those shares.
- What's Happening: Precipio signed another major hemescreen customer for $650k per year.
- What Precipio Does: Precipio Inc is a healthcare solutions company focused on cancer diagnostics.
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯週一收高超過 250 點。當內部人士購買或出售股票時,表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以認為這是他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是最近一些細價股的著名內幕交易。欲了解更多信息,請查看 本辛加的內幕交易 平台。
Theriva Biologics
塞里瓦生物製劑
- The Trade: Theriva Biologics, Inc. (NYSE:TOVX) CEO and CFO Steven A Shallcross bought a total of 25,000 shares at an average price of $0.75. To acquire these shares, it cost around $18.7 thousand.
- What's Happening: Theriva Biologics received a notice of allowance for its U.S. patent application 16/982,211 titled "Alkaline Phosphatase Agents For Treatment Of Radiation Disorders."
- What Theriva Biologics Does: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs.
- 貿易: 德里瓦生物製劑公司 紐約證券交易所代碼:TOVX)首席執行官兼首席財務官史蒂芬 A 沙爾克羅斯 買入總共二萬五千股 平均價格為 0.75 美元。要收購這些股票,其成本約為 18.7 萬美元。
- 發生了什麼事: 塞里瓦生物製劑獲得了美國專利申請補貼的通知 16/982,211 標題為「用於治療放射障礙的鹼性磷酸酶劑。」
- 塞里瓦生物製劑的作用是什麼: Theriva Biologics Inc 是一家臨床階段製藥公司,開發一種新型的單體腺病毒(OV)平台,以解決具有高度未滿足需求的破壞性癌症。
United States Antimony
美國銻
- The Trade: United States Antimony Corporation (NYSE:UAMY) Director Lloyd Bardswich acquired a total of 10,000 shares at an average price of $0.44. The insider spent around $4.4 thousand to buy those shares.
- What's Happening: On Nov. 21, 2022, United States Antimony's board approved a 5 million share stock buy back.
- What United States Antimony Does: United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company.
- 貿易: 美國銻公司 (紐約證券交易所代碼:UAMY) 導演勞埃德·巴德斯威奇 購入合共 1 萬股 平均價格為 0.44 美元。內部人士花了大約 4.4 萬美元購買這些股票。
- 發生了什麼: 2022 年 11 月 21 日,美國銻董事會批准回購 500 萬股股票。
- 美國銻有什麼作用:美國銻公司是一家完全集成的採礦,運輸,銑削,冶煉和銷售公司。
Check This Out: 5 Most Expensive Consumer Stocks You Should Worry About
看看這個: 您應該擔心的 5 種最昂貴的消費類股票
Context Therapeutics
上下文治療
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,839 shares at an average price of $0.72. To acquire these shares, it cost around $4.9 thousand.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
- 貿易: 上下文治療公司 (納斯達克:CNTX)首席執行官馬丁·勒爾 購入合共 6,839 股股份 平均價格為 0.72 美元。為了收購這些股票,它的成本約為 4.9 萬美元。
- 發生了什麼: 上下文治療和龍沙最近宣布,這些公司正在合作製造上下文的臨床開發候選人 CTIM-76。
- 什麼上下文治療: Context Theraptics Inc 是一家臨床階段的生物製藥公司,致力於改善患癌症婦女的生活。
Don't forget to check out our premarket coverage here
不要忘記在這裡查看我們的售前覆蓋範圍
Precipio
普雷西皮奧
- The Trade: Precipio, Inc. (NASDAQ:PRPO) Director Sandberg Richard acquired a total of 20,000 shares at an average price of $0.78. The insider spent $15.53 thousand to buy those shares.
- What's Happening: Precipio signed another major hemescreen customer for $650k per year.
- What Precipio Does: Precipio Inc is a healthcare solutions company focused on cancer diagnostics.
- 貿易: 普雷西皮奧公司 (納斯達克:PRPO) 董事桑德伯格理查德 購入共 2 萬股股份 平均價格為 0.78 美元。內幕人士花了 15.53 萬美元購買這些股票。
- 發生了什麼: Precipio 以每年 650 萬美元的另一位主要網頁客戶簽約。
- 普雷西皮奧做什麼: Precipio Inc 是一家專注於癌症診斷的醫療保健解決方案公司。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧